SharpePoint’s Organon & Co OGN Stock Holding History

SharpePoint’s Portfolio OGN Stock Details OGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-56,363	Closed	-$742K	–	62
2025 Q1	$742K	Buy	56,363 +14,214	+34%	+$219K	0.65%	49
2024 Q4	$629K	Buy	+42,149	New	+$687K	0.57%	46

Other funds holding OGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

SharpePoint's OGN Position: Q2 2025 in Review

SharpePoint sold out of Organon & Co (OGN) in Q2 2025, closing a stake of 56,363 shares — an estimated $742K sold.

SharpePoint first reported a position in OGN in Q4 2024 and held it in 2 quarters. The position peaked at $742K in Q1 2025. 695 funds tracked by Wall St. Rank hold OGN as of Q2 2025.

SharpePoint reported no remaining Organon & Co position as of Q2 2025 after selling out during the quarter.
SharpePoint sold 56,363 Organon & Co shares in Q2 2025, an estimated $742K.
SharpePoint first reported a position in Organon & Co in Q4 2024 and held it in 2 quarters.
SharpePoint's Organon & Co position peaked at $742K in Q1 2025.
695 funds tracked by Wall St. Rank held Organon & Co as of Q2 2025.

Based on SharpePoint's 13F filing for Q2 2025, filed 11 Aug 2025.